Immuno-oncology for Gynecologic Malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-41008-7_7
Abstract: Patients with advanced and/or recurrent gynecologic cancers derive limited benefit from currently available cytotoxic and targeted therapies. Successes of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to… read more here.
Keywords: gynecologic cancers; immuno oncology; oncology gynecologic; cancer ... See more keywords
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-018-0593-2
Abstract: Opinion statementActivity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair–deficient endometrial cancers. Other biomarkers… read more here.
Keywords: checkpoint inhibition; inhibition gynecologic; role checkpoint; gynecologic malignancies ... See more keywords
Linear accelerator-based radiosurgery and hypofractionated stereotactic radiotherapy for brain metastasis secondary to gynecologic malignancies: A single institution series examining outcomes of a rare entity
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2018.05.007
Abstract: Objective The use of SRS and fSRT to determine overall survival, tumor control, and local-disease free progression in patient diagnosed with gynecologic brain metastasis. Methods In this retrospective review, 11 patients aged 50 to 85… read more here.
Keywords: secondary gynecologic; linear accelerator; accelerator based; brain metastasis ... See more keywords
Perioperative sexual interest in women with suspected gynecologic malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.04.001
Abstract: OBJECTIVES For women with gynecologic cancer, the impact of surgery on sexual interest and desire in the immediate and later postoperative period is not well characterized. The objective of this study was to report the… read more here.
Keywords: suspected gynecologic; sexual interest; interest; oncology ... See more keywords
Indications for and complications of transfusion and the management of gynecologic malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.05.010
Abstract: Anemia, which is highly prevalent in oncology patients, is one of the most established negative prognostic factors for several gynecologic malignancies. Multiple factors can cause or contribute to the development of anemia in patients with… read more here.
Keywords: management; transfusion; blood; oncology ... See more keywords
Lower extremity lymphedema in patients with gynecologic malignancies
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-001032
Abstract: Lower extremity lymphedema is a chronic, often irreversible condition that affects many patients treated for gynecologic malignancies, with published rates as high as 70% in select populations. It has consistently been shown to affect multiple… read more here.
Keywords: extremity lymphedema; lower extremity; lymphedema patients; gynecologic malignancies ... See more keywords
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0298
Abstract: Purpose: Monalizumab binds CD94/NKG2A, preventing HLA-E inhibition of tumor lymphocytes. A dose-ranging/cohort expansion trial of monalizumab for recurrent gynecologic malignancies was conducted to determine the recommended phase II dose (RP2D) and to explore clinical activity,… read more here.
Keywords: part; ranging cohort; dose ranging; cohort expansion ... See more keywords
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217739683
Abstract: Background Patients with gynecologic malignancies are at an increased risk for venous thromboembolism. National guidelines recommend treatment of an acute venous thromboembolism with low molecular weight heparin for 5–10 days followed by long-term secondary prophylaxis… read more here.
Keywords: rivaroxaban; venous thromboembolism; patients gynecologic; oncology ... See more keywords
Early clinical progression in patients with gynecologic malignancies receiving immunomodulatory antibody therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e17087
Abstract: e17087Background: The success of immunomodulatory antibodies have led to their increasing investigation in GYN cancers. Many of these patients, however, discontinue the drugs early in treatment due... read more here.
Keywords: clinical progression; early clinical; progression patients; patients gynecologic ... See more keywords
Port Site Metastasis After Minimally Invasive Surgery in Gynecologic Malignancies: Two Case Reports and a Review of the Literature.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of women's health"
DOI: 10.2147/ijwh.s406488
Abstract: Port site metastasis (PSM) is considered an uncommon and rare complication in gynecologic malignancies with unclear treatment recommendations or guidelines. Thus, we report the treatment strategies and outcomes of two cases of PSMs following gynecologic… read more here.
Keywords: gynecologic malignancies; site metastasis; port site;
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.725330
Abstract: Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells… read more here.
Keywords: cell therapy; cancer; cell; therapy gynecologic ... See more keywords